Jing Wu, M.D., Ph.D.

Jing Wu, M.D., Ph.D.

  • Center for Cancer Research
  • National Cancer Institute
  • Building 37, Room 1142A
  • Bethesda, MD 20892
  • 240-760-6036
  • 301-480-5124
Neuro-Oncology Branch


Dr. Wu is an investigator and clinical neuro-oncologist whose clinical interests revolve around understanding challenges in neuro-oncology care and developing laboratory and clinical research programs to understand glioma biology and investigate novel therapeutic approaches to improve patient clinical outcomes. Her goal is to observe gaps in knowledge and phenotypes in clinical practice and address these questions in the laboratory to subsequently develop hypothesis-based clinical trials that can maintain the disease in a chronic state. 

There are two facets to Dr. Wu’s research. First, she seeks to understand gliomas that exhibit an aggressive phenotype and develop a diagnostic tool to monitor transformation from low-grade to high-grade disease where they exhibit rapid growth. The second aspect is to test the efficacy of TG02, a multi-kinase inhibitor, in clinical trials to understand its effects on high-grade astrocytomas or IDH-mutant gliomas. 

Areas of Expertise

1) neuro-oncology 2) neurology 3) glioma 4) translational research 5) clinical trial 6) IDH-mutant gliomas

Information for Patients

Learn about our multidisciplinary approach to patient care, our clinical trials and the highly specialized care teams who lead them.


Selected Key Publications

Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas.

Jing Wu J, Yuan Y, Priel DAL, Fink D, Peer CJ , Sissung TM, Su Y, Pang Y, Yu G, Butler MK, Mendoza TR, Vera E, Ahmad S, Bryla C, Lindsley M, Grajkowska E, Mentges K, Boris L, Antony R, Garren N, Siegel C, Lollo N, Cordova C, Aboud O, Theeler BJ, Burton EM, Penas-Prado M, Leeper H, Gonzales J, Armstrong TS, Calvo KR, Figg WD, Kuhns DB, Gallin JI, Gilbert MR.
Clinical Cancer Research. 27(12): 3298-3306, 2021. [ Journal Article ]

A Bayesian Adaptive Randomized Phase II Multicenter Trial of Bevacizumab with or without Vorinostat in Adults with Recurrent Glioblastoma.

Puduvalli VK, Wu J, Yuan Y, Armstrong TS, Vera E, Wu JM, Xu J, Giglio P, Colman H, Walbert T, Raizer J, Groves MD, Tran D, Iwamoto F, Avgeropoulos N, Paleologos N, Fink K, Peereboom D, Chamberlain M, Merrell R, Penas Prado M, Yung WKA, Gilbert MR.
Neuro-Oncology. 22: 1505–1515 , 2020. [ Journal Article ]

MerTK inhibition decreases immune suppressive glioblastoma-associated macrophages and neoangiogenesis in glioblastoma microenvironment.

Su YT, Butler M, Zhang M, Zhang W, Song H, Hwang L, Tran A, Bash RE, Schorzman AN, Pang Y, Yu G, Zamboni WC, Wang X, Frye SV, Miller, Maric C, Terabe M, Gilbert MR, Earp III HS, Wu J.
Neuro-Oncology Advances. 2(1): 1–13, 2020. [ Journal Article ]

Novel Targeting of Transcription and Metabolism in Glioblastoma

Su YT, Chen R, Wang HR, Song H, Lappin H, Vasconcelos G, Lita A, Mric D, Celiku O, Li AG, Zhang W, Larion M, Abu-Asab M, Zhuang P,Yang CZ, Gilbert MR, Wu J
Clinical Cancer Research. 24: 1124-1137, 2018. [ Journal Article ]

Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair

Lu YX, Kwintkiewicz J, Liu Y, Tech K, Frady LN, Su YT, Bautista W, Moon S, MacDonald J, Ewend ME, Gilbert MR, Yang CZ, Wu J
Cancer Research. 77: 1709-1718, 2017. [ Journal Article ]

Job Vacancies

Position Degree Required Contact Name Contact Email
Post-doctoral Fellow - Translational research, primary brain tumor Ph.D. or equivalent, M.D. or equivalent Jing Wu MD., PhD.


Postdoctoral Fellow (IRTA)
Olga Kim, M.D., Ph.D.
Postbaccalaureate Fellow (IRTA/CRTA)
Mythili Merchant
Research Fellow
Ying Pang, M.D., Ph.D.
Postbaccalaureate Fellow (IRTA/CRTA)
Alice Ranjan